Intech Investment Management LLC raised its position in Globus Medical, Inc. (NYSE:GMED – Free Report) by 37.7% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 102,132 shares of the medical device company’s stock after acquiring an additional 27,971 shares during the quarter. Intech Investment Management LLC’s holdings in Globus Medical were worth $7,650,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Paradigm Capital Management Inc. NY acquired a new position in Globus Medical during the 2nd quarter worth approximately $70,042,000. American Capital Management Inc. acquired a new stake in shares of Globus Medical in the 2nd quarter valued at $51,599,000. Hawk Ridge Capital Management LP acquired a new stake in shares of Globus Medical in the 1st quarter valued at $43,078,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Globus Medical by 107.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 912,905 shares of the medical device company’s stock worth $78,656,000 after purchasing an additional 471,875 shares during the last quarter. Finally, Janus Henderson Group PLC lifted its position in shares of Globus Medical by 4.5% during the 1st quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock worth $656,831,000 after purchasing an additional 328,217 shares during the last quarter. Institutional investors and hedge funds own 95.16% of the company’s stock.
Globus Medical Price Performance
Shares of NYSE GMED opened at $70.14 on Wednesday. Globus Medical, Inc. has a 1-year low of $69.49 and a 1-year high of $101.40. The company has a market cap of $9.29 billion, a PE ratio of 17.23, a P/E/G ratio of 1.09 and a beta of 0.98. The stock has a fifty day moving average price of $76.31 and a 200 day moving average price of $82.50.
Globus Medical (NYSE:GMED – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. Globus Medical had a net margin of 17.76% and a return on equity of 14.43%. The business had revenue of $763.72 million for the quarter, compared to analyst estimates of $792.39 million. During the same period in the previous year, the business posted $1.18 earnings per share. The business’s revenue was down .7% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. Analysts anticipate that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.
Analysts Set New Price Targets
A number of equities analysts recently commented on GMED shares. BTIG Research reiterated a “neutral” rating on shares of Globus Medical in a research note on Friday, November 6th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. Canaccord Genuity Group lowered their target price on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, November 6th. Wall Street Zen cut shares of Globus Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 7th. Finally, Truist Financial dropped their target price on shares of Globus Medical from $100.00 to $90.00 and set a “buy” rating on the stock in a research report on Monday, November 9th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $96.08.
View Our Latest Stock Analysis on GMED
Insiders Place Their Bets
In other news, Director Ann D. Rhoads sold 5,000 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total value of $425,000.00. Following the completion of the transaction, the director owned 35,384 shares in the company, valued at $3,007,640. This trade represents a 12.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director James Tobin sold 41,666 shares of the stock in a transaction dated Tuesday, November 10th. The shares were sold at an average price of $75.16, for a total transaction of $3,131,616.56. Following the completion of the transaction, the director owned 15,000 shares of the company’s stock, valued at $1,127,400. This represents a 73.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 76,666 shares of company stock valued at $5,794,017. 18.38% of the stock is owned by corporate insiders.
Globus Medical Company Profile
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Further Reading
- Five stocks we like better than Globus Medical
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
